Hypertension Management in Chronic Kidney Disease

Introduction to Guideline Recommendations

The American College of Cardiology recommends initiating ACE inhibitors or ARBs as first-line therapy for patients with CKD and uncontrolled hypertension, titrating to the highest tolerated dose, with a target blood pressure of <130/80 mmHg using standardized office measurement 1

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline suggests a target systolic BP <120 mmHg when tolerated using standardized office measurement, with an acceptable alternative range of 130-139 mmHg systolic 1, 2
For patients aged 18-49 years with CKD stages G1-G2 and BP >130/85 mmHg, the target home BP is ≤110/75 mmHg if tolerated 3
All age groups with CKD should aim for <140/90 mmHg at minimum, as recommended by the Mayo Clinic Proceedings 4, 5

ACE inhibitors or ARBs are the mandatory first-line agents for all CKD patients with hypertension, particularly those with albuminuria, according to the Kidney International guideline 1
Administer ACE inhibitors or ARBs at the highest approved dose that is tolerated, as proven benefits in clinical trials were achieved at these target doses 1
For CKD patients with diabetes and severely increased albuminuria, RAS inhibition is strongly recommended by the Kidney International guideline 1

Check serum creatinine and potassium within 2-4 weeks of initiating or increasing the dose of ACE inhibitors or ARBs, as recommended by the Kidney International guideline 1, 2, 6
Continue ACE inhibitor/ARB therapy unless serum creatinine rises by more than 30% within 4 weeks of initiation or dose increase, according to the Kidney International guideline 1, 2, 6

Add a long-acting dihydropyridine calcium channel blocker as second-line therapy when BP remains uncontrolled on ACE inhibitor or ARB monotherapy, as recommended by the Kidney International guideline 1, 2
Add a thiazide-type diuretic as third-line therapy for patients with eGFR ≥30 mL/min/1.73 m², according to the Mayo Clinic Proceedings guideline 4, 5

Hyperkalemia associated with ACE inhibitor or ARB use should be managed by measures to reduce serum potassium levels rather than decreasing the dose or stopping the RAS inhibitor, as recommended by the Kidney International guideline 1, 2, 6
Strategies include dietary potassium restriction, adding loop diuretics, or using potassium binders, according to the Kidney International guideline 1

Never combine ACE inhibitor + ARB + direct renin inhibitor, as this triple combination increases adverse events without benefit, according to the Kidney International guideline 1, 2, 6
Dual RAS inhibition (ACE inhibitor + ARB) is also not recommended due to increased risk of hyperkalemia, hypotension, and acute kidney injury, as stated in the Kidney International guideline 1, 6

Restrict dietary sodium to <2.0-2.3 g/day (<90 mmol/day) to enhance diuretic efficacy and BP control, as recommended by the Praxis Medical Insights guideline 2
Lifestyle modifications including weight loss, exercise, and smoking cessation should complement pharmacotherapy, according to the Mayo Clinic Proceedings guideline 4